Data gathered: June 18
AI Stock Analysis - Iovance Biotherapeutics (IOVA)
Analysis generated June 3, 2025. Powered by Chat GPT.
Iovance Biotherapeutics is a biotech company specializing in the development and commercialization of innovative cancer immunotherapies. The company focuses on leveraging the power of tumor-infiltrating lymphocytes (TILs) to treat cancer, providing a novel approach in the oncology therapeutic landscape.
Stock Alerts - Iovance Biotherapeutics (IOVA)
 |
Iovance Biotherapeutics | June 17 News Alert: IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA) |
|
Iovance Biotherapeutics | June 17 Employee Rating is down by 3.1% over the last month. |
|
Iovance Biotherapeutics | June 17 Business Outlook among employees is down by 9.6% over the last month. |
|
Iovance Biotherapeutics | June 16 Price is down by -8.9% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Iovance Biotherapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 17 | Sign up | Sign up | Sign up |
| Sentiment | 96 | Sign up | Sign up | Sign up |
| Webpage traffic | 27,000 | Sign up | Sign up | Sign up |
| Employee Rating | 62 | Sign up | Sign up | Sign up |
| Google Trends | 39 | Sign up | Sign up | Sign up |
| Patents | 191 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 701 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 16,215 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,731 | Sign up | Sign up | Sign up |
| Twitter Mentions | 44 | Sign up | Sign up | Sign up |
| News Mentions | 2 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 47 | Sign up | Sign up | Sign up |
| Linkedin Employees | 943 | Sign up | Sign up | Sign up |
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States.
| Price | $2.07 |
| Target Price | Sign up |
| Volume | 2,500,000 |
| Market Cap | $695M |
| Year Range | $1.66 - $12.28 |
| Dividend Yield | 0% |
| Analyst Rating | 90% buy |
| Industry | Biotechnology |
In the news
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVAJune 17 - GlobeNewswire |
|
ROSEN, A LEADING LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVAJune 17 - GlobeNewswire |
|
DEADLINE ALERT for IOVA, DNUT, and MSTR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersJune 17 - GlobeNewswire |
|
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVAJune 16 - Finnhub |
|
IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)June 16 - GlobeNewswire |
|
IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELVJune 15 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 49M | 50M | -420,000 | -116M | 0 | 0.000 |
| Q4 '24 | 74M | 46M | 28M | -79M | -75M | -0.260 |
| Q3 '24 | 59M | 40M | 19M | -84M | -89M | -0.280 |
| Q2 '24 | 31M | 37M | -5.6M | -97M | -91M | -0.340 |
| Q1 '24 | 720,000 | 13M | -12M | -113M | -108M | -0.420 |
Insider Transactions View All
| Kirby Daniel Gordon filed to buy 30,000 shares at $1.8. June 6 '25 |
| Puri Raj K. filed to buy 206,852 shares at $1.7. May 27 '25 |
| Vogt Frederick G filed to buy 374,646 shares at $1.7. May 16 '25 |
| Maynard Ryan D filed to sell 7,500 shares at $10.1. November 14 '24 |
| Dukes Iain D. filed to buy 54,000 shares at $9.2. February 20 '24 |
Similar companies
Read more about Iovance Biotherapeutics (IOVA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Iovance Biotherapeutics?
The Market Cap of Iovance Biotherapeutics is $695M.
What is the current stock price of Iovance Biotherapeutics?
Currently, the price of one share of Iovance Biotherapeutics stock is $2.07.
How can I analyze the IOVA stock price chart for investment decisions?
The IOVA stock price chart above provides a comprehensive visual representation of Iovance Biotherapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Iovance Biotherapeutics shares. Our platform offers an up-to-date IOVA stock price chart, along with technical data analysis and alternative data insights.
Does IOVA offer dividends to its shareholders?
As of our latest update, Iovance Biotherapeutics (IOVA) does not offer dividends to its shareholders. Investors interested in Iovance Biotherapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Iovance Biotherapeutics?
Some of the similar stocks of Iovance Biotherapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.